ACLY (ATP Citrate Lyase) Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas and is a Novel Predictive Radiotherapy Biomarker. This evidence concerns the gene ACLY and head and neck squamous cell carcinoma.